Beam Therapeutics Stock Analysis


USD 46.54  4.48  8.78%   

The new price hike of Beam Therapeutics could raise concerns from stakeholders as the firm is trading at a share price of 46.54 on 802,844 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.44. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Beam Therapeutics partners.
Continue to Trending Equities.
The Beam Therapeutics stock analysis report makes it easy to digest most publicly released information about Beam Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Beam Therapeutics Stock analysis module also helps to analyze the Beam Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Beam Therapeutics Stock Analysis Notes

About 82.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 4.19. Beam Therapeutics last dividend was issued on the February 4, 2014. The entity had 2:1 split on the October 26, 1990. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Beam Therapeutics please contact the company at 857 327 8775 or go to

Beam Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Beam Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Beam Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Beam Therapeutics is way too risky over 90 days horizon
Beam Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 60.27 M. Net Loss for the year was (238.29 M) with loss before overhead, payroll, taxes, and interest of (180.29 M).
Over 82.0% of the company shares are held by institutions such as insurance companies
Latest headline from Gene Therapy Biotech Prime Medicine Begins U.S. IPO Effort - Seeking Alpha

Beam Therapeutics Upcoming and Recent Events

Earnings reports are used by Beam Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Beam Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report21st of March 2022
Next Financial Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End21st of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Beam Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Beam Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Beam Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Beam Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
7th of September 2022
Other Events
30th of August 2022
Other Events
9th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
1st of August 2022
Financial Statements and Exhibits. Other Events
14th of July 2022
Unclassified Corporate Event
10th of June 2022
Submission of Matters to a Vote of Security Holders
9th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
28th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

Beam Therapeutics Thematic Classifications

In addition to having Beam Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotechnology and pharmaceuticals production and services

Beam Therapeutics Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 3.17 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Beam Therapeutics's market, we take the total number of its shares issued and multiply it by Beam Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (6.6) % which means that it has lost $6.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (38.08) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics management efficiency ratios could be used to measure how well beam therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 29th of September, Beam Therapeutics shows the mean deviation of 4.09, and Risk Adjusted Performance of 0.0909. Beam Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Beam Therapeutics, which can be compared to its rivals. Please confirm Beam Therapeutics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Beam Therapeutics is priced correctly, providing market reflects its regular price of 46.54 per share. Given that Beam Therapeutics has jensen alpha of 0.5026, we suggest you to validate Beam Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Beam Therapeutics Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Moving Average is predictive technique used to analyze Beam Therapeutics price data points by creating a series of averages of different subsets of Beam Therapeutics entire price series.

Beam Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Beam Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Beam Therapeutics Predictive Daily Indicators

Beam Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Beam Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Beam Therapeutics Forecast Models

Beam Therapeutics time-series forecasting models is one of many Beam Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Beam Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Beam Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Beam Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Beam Therapeutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Beam Therapeutics. By using and applying Beam Therapeutics Stock analysis, traders can create a robust methodology for identifying Beam Therapeutics entry and exit points for their positions.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.

Current Beam Therapeutics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Beam Therapeutics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Beam Therapeutics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Beam Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Beam Therapeutics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Beam Therapeutics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Beam Therapeutics, talking to its executives and customers, or listening to Beam Therapeutics conference calls.
Beam Therapeutics Analyst Advice Details

Beam Therapeutics Stock Analysis Indicators

Beam Therapeutics stock analysis indicators help investors evaluate how Beam Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Beam Therapeutics shares will generate the highest return on investment. By understating and applying Beam Therapeutics stock analysis, traders can identify Beam Therapeutics position entry and exit signals to maximize returns.
Quick Ratio5.59
Fifty Two Week Low27.77
Revenue Growth140,433.30%
Shares Short Prior Month11.62M
Average Daily Volume Last 10 Day1.22M
Average Daily Volume In Three Month1.21M
Shares Percent Shares Out18.84%
Gross Margins-64.76%
Short Percent Of Float21.69%
Forward Price Earnings-9.62
Float Shares54.1M
Fifty Two Week High100.06
Enterprise Value To Ebitda-31.31
Fifty Day Average59.18
Two Hundred Day Average56.50
Enterprise Value To Revenue54.02
Continue to Trending Equities. Note that the Beam Therapeutics information on this page should be used as a complementary analysis to other Beam Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Beam Therapeutics Stock analysis

When running Beam Therapeutics price analysis, check to measure Beam Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Beam Therapeutics is operating at the current time. Most of Beam Therapeutics' value examination focuses on studying past and present price action to predict the probability of Beam Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Beam Therapeutics' price. Additionally, you may evaluate how the addition of Beam Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Beam Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Beam Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.